Mesoblast (ASX:MSB) Payments of Debt: A$-113.17 Mil (TTM As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
42 GF Score
Price A$2.05
! 4 Warning Signs
View Full Analysis

What is Mesoblast Payments of Debt?

Mesoblast ASX:MSB +0.49% 42 Payments of Debt is A$-113.17 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

Mesoblast's Payments of Debt for the three months ended in Dec. 2025 was A$-102.14 Mil.

Mesoblast's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was A$-113.17 Mil.

Mesoblast Payments of Debt Related Terms

Mesoblast Payments of Debt Historical Data

* Premium members only.

The historical data trend for Mesoblast's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Payments of Debt Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.83 -82.88 -3.96 -20.36 -15.00

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.14 -6.99 -3.95 -102.14 -0.08
ASX:MSB
42GF Score
Mesoblast Ltd ASX:MSB
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$-113.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of A$-113.17 Mil mean?
Mesoblast (ASX:MSB) has a Payments of Debt of A$-113.17 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Mesoblast and its competitors.
Is Mesoblast's Payments of Debt too high?
Mesoblast's current Payments of Debt is A$-113.17 Mil. Overall, Mesoblast has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Payments of Debt compare to VRTX and REGN?
Mesoblast's Payments of Debt of A$-113.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Mesoblast and its competitors. Mesoblast's current Payments of Debt is A$-113.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Payments of Debt of A$-113.17 Mil. The current Payments of Debt is A$-113.17 Mil. Mesoblast's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Payments of Debt is A$-113.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
42GF Score

Get the complete analysis for ASX:MSB

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.05
Price